The epidemic of methylisothiazolinone contact allergy in Europe: follow-up on changing exposures.


Journal

Journal of the European Academy of Dermatology and Venereology : JEADV
ISSN: 1468-3083
Titre abrégé: J Eur Acad Dermatol Venereol
Pays: England
ID NLM: 9216037

Informations de publication

Date de publication:
Feb 2020
Historique:
received: 10 05 2019
accepted: 19 07 2019
pubmed: 17 8 2019
medline: 24 11 2020
entrez: 17 8 2019
Statut: ppublish

Résumé

Methylisothiazolinone (MI) has caused an unprecedented epidemic of contact allergy in Europe and elsewhere. Subsequently, regulatory action has been taken, at least in Europe, aiming at reducing risk of MI sensitization. To follow-up on the prevalence of contact allergy to MI in consecutively patch tested patients and assess the spectrum of products containing MI or methylchloroisothiazolinone (MCI)/MI in patients positive to MI which elicited current allergic contact dermatitis. A cross-sectional survey was performed in 2016 and 2017, including all adult patients patch tested with the baseline series (including MI 0.2% aq.) between 1 May and 31 October at 14 centres in 11 European countries. Patients with positive reactions (+ to +++) to MI were further examined regarding history, clinical characteristics and eliciting products, which were categorized into 34 types and 4 classes (leave-on, rinse-off, household, occupational). The results were compared with the reference year 2015. A total of 317 patients, n = 202 of 4278 tested in 2016 (4.72%) and n = 115 of 3879 tested in 2017 (2.96%), had positive reactions to MI; the previous result from 2015 was 5.97% (P < 0.0001). The share of currently relevant contact allergy among all positive reactions declined significantly as well (P = 0.0032). Concerning product classes, a relative decline of leave-on and a relative increase of rinse-off and household products was noted. The prevalence of MI contact allergy decreased by 50% from 2015 to 2017. As a consequence of regulation, the share of cosmetics products (leave-on in particular) eliciting allergic contact dermatitis is decreasing. The chosen method of analysing causative products in sensitized patients has proven useful to monitor effects of intervention.

Sections du résumé

BACKGROUND BACKGROUND
Methylisothiazolinone (MI) has caused an unprecedented epidemic of contact allergy in Europe and elsewhere. Subsequently, regulatory action has been taken, at least in Europe, aiming at reducing risk of MI sensitization.
OBJECTIVE OBJECTIVE
To follow-up on the prevalence of contact allergy to MI in consecutively patch tested patients and assess the spectrum of products containing MI or methylchloroisothiazolinone (MCI)/MI in patients positive to MI which elicited current allergic contact dermatitis.
METHODS METHODS
A cross-sectional survey was performed in 2016 and 2017, including all adult patients patch tested with the baseline series (including MI 0.2% aq.) between 1 May and 31 October at 14 centres in 11 European countries. Patients with positive reactions (+ to +++) to MI were further examined regarding history, clinical characteristics and eliciting products, which were categorized into 34 types and 4 classes (leave-on, rinse-off, household, occupational). The results were compared with the reference year 2015.
RESULTS RESULTS
A total of 317 patients, n = 202 of 4278 tested in 2016 (4.72%) and n = 115 of 3879 tested in 2017 (2.96%), had positive reactions to MI; the previous result from 2015 was 5.97% (P < 0.0001). The share of currently relevant contact allergy among all positive reactions declined significantly as well (P = 0.0032). Concerning product classes, a relative decline of leave-on and a relative increase of rinse-off and household products was noted.
CONCLUSION CONCLUSIONS
The prevalence of MI contact allergy decreased by 50% from 2015 to 2017. As a consequence of regulation, the share of cosmetics products (leave-on in particular) eliciting allergic contact dermatitis is decreasing. The chosen method of analysing causative products in sensitized patients has proven useful to monitor effects of intervention.

Identifiants

pubmed: 31419348
doi: 10.1111/jdv.15875
doi:

Substances chimiques

Thiazoles 0
2-methyl-4-isothiazolin-3-one 229D0E1QFA

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

333-339

Subventions

Organisme : EADV
ID : 2015-015

Commentaires et corrections

Type : CommentIn

Informations de copyright

© 2019 The Authors. Journal of the European Academy of Dermatology and Venereology published by John Wiley & Sons Ltd on behalf of European Academy of Dermatology and Venereology.

Références

Dillarstone A. Cosmetic preservatives. Contact Dermatitis 1997; 37: 190.
Methylisothiazolinone, quo vadis? Contact Dermatitis 2016; 75: 263-264.
SCCS. Scientific committee on consumer safety, opinion on methylisothiazolinone (p 94) - submission ii, 12 December 2013, sccs/1521/13, revision of 27 march 2014., European Commission, 2014.
SCCS. Scientific committee on consumer safety, opinion on methylisothiazolinone (mi) (p 94) sensitisation only, 25 June 2015, sccs/1557/15, final opinion December 2015., European Commission, 2015.
Schwensen JF, Uter W, Bruze M et al. The epidemic of methylisothiazolinone: a European prospective study. Contact Dermatitis 2017; 76: 272-279.
Ljubojević Hadžavdić S, Uter W, Ilijanić Samošćanec M, Johansen JD. Methylisothiazolinone contact allergy in Croatia: epidemiology and course of disease following patch testing. Contact Dermatitis 2018; 79: 162-167.
Johansen JD, Aalto-Korte K, Agner T et al. European Society of Contact Dermatitis guideline for diagnostic patch testing - recommendations on best practice. Contact Dermatitis 2015; 73: 195-221.
Uter W, Schnuch A, Gefeller O. Guidelines for the descriptive presentation and statistical analysis of contact allergy data. Contact Dermatitis 2004; 51: 47-56.
Urwin R, Craig S, Latheef F, Wilkinson M. Methylisothiazolinone: the epidemic is declining - but not gone. Contact Dermatitis 2017; 76: 301-302.
Venables ZC, Bourke JF, Buckley DA et al. Has the epidemic of allergic contact dermatitis due to methylisothiazolinone reached its peak? Br J Dermatol 2017; 177: 276-278.
Flury U, Palmer A, Nixon R. The methylisothiazolinone contact allergy epidemic in Australia. Contact Dermatitis 2018; 79: 189-191.
Kluger N. Contact allergy to moisturizers in Finland: the tale of the lurking tube in the medicine cupboard. Contact Dermatitis 2018; 78: 289-290.
Yazar K, Lundov MD, Faurschou A et al. Methylisothiazolinone in rinse-off products causes allergic contact dermatitis: a repeated open-application study. Br J Dermatol 2015; 173: 115-122.
Thomsen AV, Schwensen JF, Bossi R et al. Isothiazolinones are still widely used in paints purchased in five European countries: a follow-up study. Contact Dermatitis 2018; 78: 246-253.
Sechi A, Vincenzi C, Tengattini V et al. Airborne dermatitis in a child caused by isothiazolinones in a water-based paint in Italy: call for better regulations. Contact Dermatitis 2018; 79: 45-46.
Todberg T, Opstrup MS, Johansen JD, Hald M. Occupational facial contact dermatitis caused by methylchloroisothiazolinone/methylisothiazolinone in a stainless steel aerosol spray. Contact Dermatitis 2017; 77: 173-174.
Andersson AM, Opstrup MS, Zachariae C et al. The importance of a complete declaration of isothiazolinones in products beyond cosmetics. Contact Dermatitis 2017; 77: 171-172.
Schwensen JF, Menné Bonefeld C, Zachariae C et al. Cross-reactivity between methylisothiazolinone, octylisothiazolinone and benzisothiazolinone using a modified local lymph node assay. Br J Dermatol 2017; 176: 176-183.
Herman A, Aerts O, de Montjoye L et al. Isothiazolinone derivatives and allergic contact dermatitis: a review and update. J Eur Acad Dermatol Venereol 2019; 33: 267-276.
Sukakul T, Kanchanapenkul D, Bunyavaree M et al. Methylchloroisothiazolinone and/or methylisothiazolinone in cosmetic products - A market survey. Contact Dermatitis 2019; 80: 110-113.
Madsen JT, Andersen KE, Nielsen DT et al. Undisclosed presence of methylisothiazolinone in ‘100% natural’ Konjac sponge. Contact Dermatitis 2016; 75: 308-309.
El-Houri RB, Christensen LP, Persson C et al. Methylisothiazolinone in a designer spectacle frame - a surprising finding. Contact Dermatitis 2016; 75: 310-312.
Bennike NH, Johansen JD, Zachariae C. Please, label the label; a case report of occupational allergic contact dermatitis caused by methylisothiazolinone in adhesive labels. Contact Dermatitis 2016; 75: 314-315.

Auteurs

W Uter (W)

Department of Medical Informatics, Biometry and Epidemiology, University of Erlangen/Nürnberg, Erlangen, Germany.

K Aalto-Korte (K)

Occupational Medicine, Finnish Institute of Occupational Health, Helsinki, Finland.

T Agner (T)

Department of Dermatology, Bispebjerg Hospital, University of Copenhagen, Copenhagen, Denmark.

K E Andersen (KE)

Department of Dermatology and Allergy Centre, Odense University Hospital, University of Southern Denmark, Odense, Denmark.

A J Bircher (AJ)

Department of Dermatology, University Hospital Basel, Basel, Switzerland.

R Brans (R)

Institute for Interdisciplinary Dermatological Prevention and Rehabilitation (iDerm) at the University of Osnabrück, Osnabrück, Germany.

M Bruze (M)

Department of Occupational and Environmental Dermatology, Skåne University Hospital, Lund University, Malmö, Sweden.

T L Diepgen (TL)

Department of Social Medicine, Occupational and Environmental Dermatology, University of Heidelberg, Heidelberg, Germany.

C Foti (C)

Unit of Dermatology, Department of Biomedical Science and Human Oncology, University of Bari, Bari, Italy.

A Giménez Arnau (A)

Department of Dermatology, Hospital del Mar, IMIM, Universitat Autònoma de Barcelona, Barcelona, Spain.

M Gonçalo (M)

Department of Dermatology, University Hospital and Faculty of Medicine, University of Coimbra, Coimbra, Portugal.

A Goossens (A)

Contact Allergy Unit, Department of Dermatology, University Hospital KU Leuven, Leuven, Belgium.

J McFadden (J)

Guy's Hospital, St John's Institute of Dermatology, London, UK.

E Paulsen (E)

Department of Dermatology and Allergy Centre, Odense University Hospital, University of Southern Denmark, Odense, Denmark.

C Svedman (C)

Department of Occupational and Environmental Dermatology, Skåne University Hospital, Lund University, Malmö, Sweden.

T Rustemeyer (T)

Department of Dermatology, Amsterdam University Medical Centres, Amsterdam, The Netherlands.

I R White (IR)

Guy's Hospital, St John's Institute of Dermatology, London, UK.

M Wilkinson (M)

Department of Dermatology, Leeds Teaching Hospitals NHS Trust, Leeds, UK.

J D Johansen (JD)

Department of Dermato-Allergology, National Allergy Research Centre, Gentofte Hospital, University of Copenhagen, Hellerup, Denmark.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH